Copy Link Print Information

Ravoxertinib

(Synonyms: GDC-0994)
51 Cited Publications
Revisión del cliente

Based on 51 publication(s) in Google Scholar

Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza: 99.74%
  • No. CAS: 1453848-26-4
  • Fòrmula: C21H18ClFN6O2
  • Peso molecular:440.86
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Ravoxertinib Chemical Structure
    Ravoxertinib Chemical Structure
  • Experimental Validation Results for Ravoxertinib
  • Experimental Validation Results for Ravoxertinib
  • Experimental Validation Results for Ravoxertinib
  • Experimental Validation Results for Ravoxertinib
  • Experimental Validation Results for Ravoxertinib
  • Experimental Validation Results for Ravoxertinib
No. CAS: 1453848-26-4
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Ravoxertinib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Ravoxertinib

More
Customer Validation & Images
RT-PCRCell Proliferation/Viability AssayIP
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • RT-PCR
  • IP
  • RT-PCR
  • RT-PCR

Ver todos los productos específicos de isoformas ERK

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Ravoxertinib Chemical Structure
    Ravoxertinib Chemical Structure
    1/16
  • 1/16

    Ravoxertinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Jan 21;17(1):1902. [Abstract]

    Customer Validation
     U87, U251, and H1299 cells, with or without EGFR R252C mutation were treated with or without 5 μM Ravoxertinib. Cell proliferation was assessed at day 7. Relative proliferation was calculated using vehicle-treated EGFR WT cells as the control.

  • 1/16

    Ravoxertinib purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jan;637(8046):726-735. [Abstract]

    Customer Validation
     Investigation of the signalling axis regulating LIF expression upon PDGF stimulation. Cells were treated with ERK inhibitor ravoxertinib (10 μM) for 24 h before cell lysis for total RNA extraction and measurement of LIF mRNA levels by real-time qPCR.

  • 1/16

    Ravoxertinib purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Feb;20(2):175-188. [Abstract]

    Customer Validation
     Effects of kinase inhibitors on ISO-triggered inhibition of SeV-induced transcription of the IFNB1 gene. THP1 cells were treated with the ERK inhibitor GDC-0994 (1 μM) for 1 h and then were treated with ISO (10 μM) and infected with SeV (MOI = 1). Six hours later, a qPCR analysis to determine the mRNA levels of the IFNB1 gene was performed. The results are shown as the inhibition rate (%).

  • 1/16

    Ravoxertinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Sep 30;14(1):6117. [Abstract]

    Customer Validation
     HCT116 cells were pretreated with PPP (1 μM), ARQ-092 (2 μM) and GDC-0994 (Ravoxertinib, 10 μM) for 1 h before being cultured under hypoxia for 12 h.

  • 1/16

    Ravoxertinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 Jul 13;42(1):166. [Abstract]

    Customer Validation
     The effect of NF-κB, ERK, JNK and p38 inhibitors on IL-1β-induced Saa3 expression in vivo. One hour after intravenous administration of Ravoxertinib, IL-1β (20 ng in 100 ul saline) were i.v. administrated into the mice. Six hours later, lung Saa3 expression was detected by qPCR.

  • 1/16

    Ravoxertinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 Jul 13;42(1):166. [Abstract]

    Customer Validation
     The effect of NF-κB, ERK, JNK and p38 inhibitors on IL-1β-induced Saa3 expression in MLE-12 cells. MLE-12 cells were pre-treated with Ravoxertinib for 1 h, then stimulated with IL-1β (10 ng/ml) for 6 h. Saa3 expression was detected by qPCR.

  • Ravoxertinib